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Abstract
Aims Signiﬁcant mitral regurgitation (MR) is an important predictor for all-cause mortality and heart failure (HF) hospitaliza-
tions independent of left ventricular ejection fraction (LVEF). The aims of this study were to investigate (i) in how many pa-
tients referred to a tertiary outpatient HF clinic HF therapy could be optimized, (ii) the effect of optimized treatment on
MR severity, and (iii) whether a reduction in MR resulted in improvement of symptoms.
Methods and results Forty-seven referred patients with therapy-resistant symptomatic chronic HF with an LVEF <40% and
at least moderate MR were analysed on admission and after optimization of HF treatment after 6–18 months. The patients
were classiﬁed as a volume responder when LV end-systolic volume (LVESV) decreased ≥15%, as LVEF responder when LVEF
increased by ≥5% points, as clinical responder when New York Heart Association (NYHA) class improved at least one category,
and as MR responder when MR severity improved at least one category to maximally moderate. After 14 ± 4 months of treat-
ment optimization, optimal doses of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker were seen in 18
(38%) patients compared with three (6%) at baseline (P < 0.001), and optimal doses of beta-blockers were seen in 14
(30%) patients compared with four (9%) at baseline (P < 0.001). In total, 68% of the patients were clinical responders, 57%
MR responders, 34% volumetric responders, and 49% LVEF responders. NYHA class improved from 2.9 ± 0.6 to 2.0 ± 0.9
(P < 0.001), MR class from 5.2 ± 0.8 to 3.6 ± 1.5 (P < 0.001), LVEF from 24% ± 9% to 31% ± 12% (P < 0.01), and LVESV
non-signiﬁcantly improved. The positive predictive value of MR response to NYHA response was 88%; the negative predictive
value was 53%, agreement 69%, and kappa 0.39. The positive predictive value of LVEF response to NYHA response was 76%;
the negative predictive value was 44%, agreement 60%, and kappa 0.21. The positive predictive value of LVESV volume re-
sponse to NYHA response was 75%; the negative predictive value was 39%, agreement 51%, and kappa 0.12.
Conclusions Although this study was limited by a small number of patients, initiation and up-titration of recommended HF
therapy in patients referred to our tertiary HF outpatient clinic resulted in signiﬁcant MR reduction in over half of the patients,
emphasizing the importance of optimal medical treatment in these very sick cardiac patients with otherwise grave prognosis.
MR reduction was best correlated to NYHA improvement.
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Introduction
Both in ischaemic and non-ischaemic cardiomyopathy, the
presence of signiﬁcant mitral regurgitation (MR) is an impor-
tant predictor for all-cause mortality and heart failure (HF)
hospitalizations independent of left ventricular ejection
fraction (LVEF).1 To date, the most effective therapies for sec-
ondary MR are aimed at the underlying LV dysfunction. Given
the main pathophysiological mechanism, that is, LV and annu-
lar dilatation, these include optimal medical HF therapy and
cardiac resynchronization therapy (CRT) when appropriate.
In particular, beta-blockers and angiotensin-converting
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enzyme inhibitors (ACE-Is) are recommended for all patients
with LV dysfunction and secondary MR.2 By reversing LV
unloading and LV remodelling, optimal HF therapy may re-
duce MR. Surprisingly, however, few studies have examined
the effect of beta-blockers3–6 or ACE-Is7 therapies on second-
ary MR. Secondary MR may also dramatically improve after
optimization of ﬂuid status by diuretics through lowering of
the LV ﬁlling pressures.8 More robust data are available on
the LV remodelling and synchronizing effects of CRT on sec-
ondary MR.9–14
In this study, we report our results in patients with chronic
HF and at least moderate MR referred to our tertiary HF out-
patient clinic for a second opinion, speciﬁc referral for MR in-
tervention, and/or heart transplantation. The aims of this
study were to investigate (i) in how many real-world referred
patients HF therapy could be optimized, (ii) the effect of op-
timized treatment on MR severity, and (iii) whether a reduc-
tion in MR resulted in an improvement of symptoms.
Methods
Study patient deﬁnition
All patients included in the study fulﬁlled the following inclu-
sion criteria: (i) referred by a cardiologist to our tertiary HF
outpatient clinic between 2005 and 2015 for a second opin-
ion with (ii) therapy-resistant symptomatic chronic HF New
York Heart Association (NYHA) class 2 to 4, (iii) LVEF <40%,
and (iv) at least moderate MR. In addition, all included pa-
tients were required to have a baseline transthoracic echo-
cardiogram before change in HF treatment at our tertiary
HF outpatient clinic and a follow-up transthoracic echocardio-
gram between 6 and 18 months. Exclusion criteria were prior
valvular surgery and concomitant congenital heart disease.
Clinical data
The following variables were noted: gender, age, heart rate,
systolic blood pressure, aetiology of HF, prior HF hospitaliza-
tion in the last 12 months, NYHA class, and renal dysfunction
[deﬁned as estimated glomerular ﬁltration rate (eGFR)
< 45 mL/min/1.73 m2].
Transthoracic echocardiography
Echocardiography was performed with a Sonos or iE33 sys-
tem (Philips, Best, The Netherlands), equipped with an S5-1
transducer according to a standard HF protocol. The following
variables were measured both at baseline and follow-up ac-
cording to standard guidelines15–17: LV end-diastolic diameter
and volumes, LV end-systolic diameter and volumes (LVESV),
LVEF, left atrial (LA) diameter and volume, transmitral E-
wave, transmitral deceleration time, diastolic early septal wall
velocity as assessed with tissue Doppler imaging (e′), tricuspid
valve regurgitation velocity, caval vein diameter, MR severity
[according to seven scales (from 0 to 6): none, trivial, mild,
mild to moderate, moderate, moderate to severe, and se-
vere],17 and MR jet morphology in the LA (central or eccen-
tric). LV volumes and LVEF were measured with TomTec
triplane analysis in Imaging Arena (TomTec Imaging systems,
Imaging Arena, version 4.6, Unterschleissheim, Germany).
All measurements were performed by blinded observers:
MR by M. L. G., LV volumes and ejection fraction by E. S.,
and all others by L. d. G. d. L.
Deﬁnition of responders
A patient was considered a volume responder when LVESV
decreased ≥15%, an LVEF responder when LVEF increased
by ≥5% points, a clinical responder when NYHA class im-
proved at least one category, and an MR responder when
MR severity improved at least one category to maximally
moderate.
Medication and devices
In all patients, the following drugs (including dosage) were
noted at baseline and at the time of follow-up echocardiogra-
phy: ACE-I or angiotensin receptor blocker (ARB), beta-
blocker, loop diuretic, mineralocorticoid receptor antagonist
(MRA), and digoxin. Optimal treatment dosages were deﬁned
according to the guideline.2 Also, other interventions like thy-
roid hormone or Vitamin-D supplementation were noted. Fi-
nally, it was noted whether the patient had an implantable
cardioverter deﬁbrillator (ICD) or had undergone (upgrade
to) CRT.
Statistical analysis
Statistical analysis was performed using SPSS version 21.0.0.1
(SPSS, IBM, Armonk, NY). Categorical data are presented as
numbers and percentages, whereas continuous data are sum-
marized as mean ± standard deviation or median value with
range. Comparisons of proportions were performed with a
two-sided Z test. P-values <0.05 were considered signiﬁcant.
The agreement between MR response, EF response, and
LVESV volume response to the NYHA response was assessed
by calculating the kappa coefﬁcient (a value of 0.21 to 0.40 in-
dicating a fair agreement, a value of 0.41 to 0.80 indicating a
moderate agreement, and a value of >0.80 indicating an ex-
cellent agreement).
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Results
Baseline clinical and echocardiographic
characteristics
Forty-seven patients (mean age 52 ± 13 years, 68% male pa-
tients) were included in the study, see Figure 1. As seen in
Table 1, heart rate was 81 ± 19 b.p.m., and systolic blood pres-
sure 102 ± 15 mmHg. HF aetiologies were ischaemic in 14
(30%) patients, 25 (53%) patients were hospitalized because
of HF in the previous 12 months, and NYHA class was
2.9 ± 0.6 [NYHA 2 in 11 (23%), NYHA 3 in 30 (64%), and NYHA
4 in 6 (13%)]. Signiﬁcant renal dysfunction was present in 12
(26%) patients. Mean volumes were 265 ± 103 mL for LV
end-diastolic volume and 205 ± 97 mL for LVESV, and LVEF
was 25% ± 9%. Moderate, moderate-to-severe, and severe
MR was present in 11 (23%), 15 (32%), and 21 (45%) patients.
As seen in Table 2, ACE-I/ARBs were present in 45 (96%) pa-
tients, beta-blockers in 37 (79%), diuretics in 42 (89%), MRAs
in 32 (68%), and digoxin in 12 (26%). However, optimal doses
of ACE-I/ARBs were present in three (6%) patients, and opti-
mal doses of beta-blockers in four (9%). CRT was present in
10 (21%) patients (CRT-D in nine and CRT-P in one), and an iso-
lated ICD was present in 13 (28%) patients.
Medical interventions
Ten patients (21%) were immediately after ﬁrst outpatient
assessment hospitalized to optimize HF. As seen in Table 2
and Figure 2, in the total group of patients, ACE-I/ARBs
were initiated in two (4%) patients and up-titrated in 22
(47%) patients, beta-blockers were initiated in nine (19%)
patients and up-titrated in 20 (43%) patients, diuretics were
initiated in three (6%) patients and up-titrated in 22 (47%)
patients, MRAs were initiated in seven (15%) patients and
up-titrated in three (6%) patients, and digoxin was initiated
in 25 (52%) patients and up-titrated in none. At follow-up,
optimal doses of ACE-I/ARBs were present in 18 (38%)
Figure 1 Inclusion patients. HF, heart failure; LVAD, left ventricular assist device; MR, mitral regurgitation; MVP, mitral valve plasty.
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Table 2 Baseline heart failure therapy and changes in the study population (n = 47)
Baseline Follow-up
At referral Optimal dose Up-titration Initiation Finally Optimal dose
ACE-inhibitors/ARBs 45 (96%) 3 (6%) 22 (47%) 2 (4%) 47 (100%) 18 (38%)*
Beta-blocker 37 (79%) 4 (9%) 20 (43%) 9 (19%) 46 (98%) 14 (30%)*
Diuretics 42 (89%) 22 (47%) 3 (6%) 45 (96%)
MRAs 32 (68%) 3 (6%) 7 (15%) 39 (83%)
Digoxin 12 (26%) 0 (0%) 25 (53%) 37 (76%)
CRT-P 1 (2%) 0 (0%) 1 (2%)
CRT-D 9 (19%) 8 (17%)a 17 (36%)
ICD only 13 (28%) 5 (11%) 15 (32%)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy deﬁbrillator; CRT-P,
cardiac resynchronization therapy pacemaker; ICD, implantable cardioverter deﬁbrillator; MRAs, mineralocorticoid receptor antagonists.
aIncluding three upgrades from ICD only.
*P < 0.001 compared with baseline.
Table 1 Clinical and echocardiographic data
All patients
baseline N = 47
All patients
follow-up N = 47 MR responder N = 27 MR non-responder N = 20
Clinical data
Male gender 32 (68%) 17 (63%) 15 (75%)
Age (years) 52 ± 13 56 ± 12 49 ± 13
Heart rate (bpm) 81 ± 19 66 ± 12 85 ± 20 77 ± 16
Systolic blood pressure 102 ± 15 101 ± 13 103 ± 18
Ischaemic aetiology 14 (30%) 8 (30%) 6 (30%)
Prior HF hospitalization 25 (53%) 15 (56%) 10 (50%)
NYHA class III or IV 36 (77%) 12 (26%) 21 (78%) 15 (75%)
Glomerular
ﬁltration rate
61 ± 20 58 ± 21 64 ± 22 56 ± 14
Renal dysfunctiona 12 (26%) 10 (21%) 7 (26%) 5 (25%)
Echocardiographic datab
LVEDD 68.4 ± 13.2 66.8 ± 11.9 68.3 ± 12.8 68.4 ± 13.8
LVEDD delta 1.6 ± 11.2 4.8 ± 13.5 1.1 ± 8.2
LVESD 61.3 ± 13.8 56.4 ± 13.1 60.8 ± 13.4 61.6 ± 14.5
LVESD delta 4.9 ± 11.1* 8.0 ± 13.4* 2.3 ± 8.1
LVEDV 264.6 ± 102.6 246.5 ± 100.3 272.7 ± 119.6 257.8 ± 88.6
LVEDV delta 18.1 ± 86.6 48.0 ± 112.6 6.9 ± 46.1
LVESV 204.8 ± 97.0 179.5 ± 99.1 210.4 ± 113.5 200.0 ± 83.6
LVESV delta 25.3 ± 89.9 54.2 ± 120.5 0.9 ± 42.7
LVEF 24.5 ± 9.3 30.7 ± 11.7 25.3 ± 9.4 24.0 ± 9.4
LVEF delta 6.1 ± 12.2# 9.0 ± 16.2* 3.7 ± 7.0*
LA diameter 49.5 ± 7.8 46.4 ± 9.0 47.9 ± 7.1 50.9 ± 8.3
LA diameter delta 3.1 ± 8.1# 6.7 ± 8.3# 0.1 ± 6.8
LA volume 117.1 ± 37.7 102.6 ± 49.6 115.1 ± 36.0 118.8 ± 39.9
LA volume delta 14.5 ± 52.1 41.8 ± 37.4# 8.5 ± 52.4
e′ 4.7 ± 1.7 5.2 ± 2.0 4.4 ± 1.8 4.9 ± 1.7
e′ delta 0.5 ± 1.9 0.5 ± 1.9 0.5 ± 1.9
E/e′ 22.5 ± 9.1 17.6 ± 12.1 24.0 ± 10.6 21.2 ± 7.7
E/e′ delta 4.9 ± 13.2* 8.6 ± 13.9* 1.8 ± 12.2
TR velocity 2.9 ± 0.6 2.6 ± 0.8 2.9 ± 0.6 3.0 ± 0.6
TR velocity delta 0.3 ± 0.8* 0.6 ± 0.7# 0.1 ± 0.7
IVC diameter 20.9 ± 5.2 16.3 ± 4.9 20.1 ± 5.5 21.5 ± 5.0
IVC diameter delta 4.6 ± 5.6# 5.3 ± 6.1# 3.9 ± 5.2#
MR central jet 26 (55%) 26 (55%) 16 (59%) 10 (50%)
MR severe 21 (45%) 6 (13%) 13 (48%) 8 (40%)
HF, heart failure; IVC, inferior vena cava; LA, left atrium; LVEDD, left ventricular end-diastolic diameter; LVEDV, LV end-diastolic volume;
LVEF, LV ejection fraction; LVESD, LV end-systolic diameter; LVESV, LV end-systolic volume; MR, mitral regurgitation; NYHA, New York
Heart Association; TR, tricuspid regurgitation.
aGlomerular ﬁltration rate <45 mL/min/1.73 m2.
bIn the MR responder columns, only baseline and delta values are displayed. Limited to the 35 patients with complete echo data available.
*P < 0.05.
#P < 0.01.
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patients compared with three (6%) at baseline (P < 0.001),
and optimal doses of beta-blockers were present in 14
(30%) patients compared with four (9%) at baseline
(P < 0.001). Six (13%) patients were on the evidence-based
dose of both beta-blockers and ACE-inhibitors/ARBs at the
time of follow-up echocardiography vs. 0 (0%) at baseline.
Heart rate decreased from 81 ± 19 to 66 ± 12 b.p.m.
(P < 0.001).
Device interventions
As seen in Table 2, CRT was initiated in eight (17%) patients,
of whom in three patients, existing ICD therapy was upgraded
to a CRT-D system. An additional ﬁve patients received an iso-
lated ICD.
Clinical and echocardiographic improvement
After a mean of 14 ± 4 months, NYHA class improved from
2.9 ± 0.6 to 2.0 ± 0.9 (P < 0.001), and 32 patients (68%) were
clinical responders. MR class improved from 5.2 ± 0.8 to
3.6 ± 1.5 (P < 0.001), and 27 patients (57%) were MR re-
sponders (Figure 3). In these latter patients, vena contracta
width improved from 7.0 ± 1.4 to 2.7 ± 1.2 mm
(P < 0.001), whereas in the non-responders, no signiﬁcant
improvement was seen in vena contracta width (7.3 ± 1.5
vs. 6.9 ± 1.6 mm, P = not signiﬁcant).
Left ventricular end-systolic volume non-signiﬁcantly im-
proved from 205 ± 97 to 180 ± 99 mL (P = not signiﬁcant),
and 12 patients (34%) were volumetric responders. LVEF
improved from 24% ± 9% to 31% ± 12% (P < 0.01), and 17
patients (49%) were LVEF responders.
Predictors for mitral regurgitation improvement
As seen in Table 1, none of the baseline variables predicted
improvement (responders) in MR. Associated with MR im-
provement were a decrease in LV end-systolic diameter, LA
diameter and volume, E/e′, tricuspid regurgitation velocity
and inferior vena cava dimension, and an increase in LVEF.
Figure 2 Baseline (left) and change (right) in heart failure therapy. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT-D,
cardiac resynchronization therapy deﬁbrillator; MRA, mineralocorticoid receptor antagonist.
Figure 3 New York Heart Association (NYHA) class (left) and mitral regurgitation (MR) (right) response to optimize treatment. Thickness of the line
corresponds to the number of patients.
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Relation between mitral regurgitation and
ejection fraction improvement vs. New York
Heart Association response
The positive predictive value of MR response to NYHA re-
sponse was 88%; the negative predictive value was 53%,
agreement 69%, and kappa 0.39. The positive predictive
value of LVEF response to NYHA response was 76%; the neg-
ative predictive value was 44%, agreement 60%, and kappa
0.21. The positive predictive value of LVESV volume response
to NYHA response was 75%; the negative predictive value
was 39%, agreement 51%, and kappa 0.12.
Relation between mitral regurgitation
improvement and renal dysfunction
Estimated glomerular ﬁltration rate non-signiﬁcantly de-
creased from 61 ± 20 to 58 ± 21 mL/min/1.73 m2. In MR re-
sponders, eGFR remained stable (0 ± 13), whereas in MR
non-responders, eGFR deteriorated with 8 ± 12 mL/min/
1.73 m2 (P < 0.05). In both EF responders and non-
responders, eGFR remained stable.
Discussion
The main ﬁndings of this study in patients referred by car-
diologists to our tertiary HF clinic with therapy-resistant HF
and at least moderate MR are (i) although the vast majority
of the referred patients received recommended medication,
optimal dosages were seen in only a very small minority,
(ii) initiation of therapy resulted in the presence of the rec-
ommended medication in virtually all patients, (iii) despite
up-titration of recommended medication in almost half of
the patients, still approximately only one-third of patients
could tolerate the maximum recommended drug dosages,
(iv) MR reduced signiﬁcantly in over half of the patients,
and (v) MR reduction best correlated to NYHA
improvement.
Medical therapy
Medical therapy for HF consists of vasodilators (ACE-Is),
beta-blockers, MRAs, and diuretics. The main effects of
these drugs include reversal or delay of LV remodelling
and reduction of MR through lowering ﬁlling pressures.
The use of afterload-reducing agents, including ACE-Is, might
reduce MR volume and improve LV forward stroke volume
by decreasing the pressure gradient between the LV and
the left atrium through systolic unloading. A similar effect
of reduction in MR is obtained with preload reduction
through the use of diuretics that decrease LV size and
tethering with a consequent decrease in MR volume.8 It is
well known that ACE-Is and beta-blockers reduce mortality
and morbidity in symptomatic patients with HF with re-
duced LVEF18–20 and are complementary. According to the
guideline, these drugs should be gradually up-titrated to
the maximum tolerated dose.2 In this study, it is shown that
although referred patients often were on ACE-Is and beta-
blockers, optimal doses were rarely seen. In a signiﬁcant
number of patients, beta-blockers could be initialized by
the HF specialist, and drugs could be up-titrated. Still, at
the last moment of assessment (between 6 and 18 months),
optimal doses of ACE-Is and beta-blockers were only seen in
one-third of our patients. Hypotension, bradycardia, and re-
nal failure are well-known causes of failure to up-titrate HF
drugs, in particular in patients with advanced HF. Patients
referred to our outpatient HF clinic represent the sickest
of the sick: the majority were hospitalized because of HF
in the previous 12 months, and outpatient NYHA class was
in the vast majority NYHA class 3 or 4. Further evidence
for the severity of HF disease is seen in the haemodynamic
characteristics. The mean heart rate of 81 is quite compara-
ble with patients included in the major HF landmark tri-
als,18–20 but the systolic blood pressure of 102 mmHg is
signiﬁcantly lower than the 120–130 mmHg range reported
in the major HF landmark trials18–20 that included also
mainly patients in NYHA class 3 or 4.
Despite these issues, the subscription of ACE-Is and beta-
blockers in 100% and 98% of patients is a remarkable
achievement. For example, in a Spanish prospective cohort
of patients hospitalized for HF from 2008 to 2011, beta-
blockers were after 12 months only present in 68% of pa-
tients,21 and numbers also seen in other registries like the
Organized Program to Initiate Lifesaving Treatment in Hospi-
talized Patients With Heart Failure (OPTIMIZE-HF) registry.22
In this latter trial, target doses of metoprolol and carvedilol
were seen in only 8% and 18% of patients 3 months after
discharge.
In the recently published European Society of Cardiology
Heart Failure Long-Term Registry, patients with chronic HF
had 1 year follow-up ACE-Is/ARBs, beta-blockers, and MRAs
in 87%, 89%, and 59% of patients, respectively.23 In these tri-
als, baseline values of systolic blood pressure and heart rate
were 124 ± 21mmHg and 73 ± 15 b.p.m., and 25% of patients
were in NYHA class III or IV. So our patients referred because
of refractory HF were also compared with this contemporary
registry clearly the sickest of the sick.
Device therapy
According to the baseline LVEF, 63% of patients who had a
primary prophylactic ICD indication had an ICD (with or with-
out CRT) implanted before referral. At the end of the follow-
up period, this percentage was 94%; in addition, all patients
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with left bundle branch block had CRT. These numbers seem
also much better than the low numbers reported in the Euro-
pean Society of Cardiology Heart Failure Long-Term Registry,
although it cannot be clearly distillated from this registry how
many patients actually had a clear indication for CRT and/or
ICD.23
Mitral regurgitation
In HF patients, the presence of signiﬁcant MR is a signiﬁcant
predictor for mortality1,24,25 and exercise capacity.26 By inclu-
sion, all our patients had at least moderate MR. The de-
scribed therapeutic interventions resulted in a signiﬁcant
reduction of MR in over half of the patients, consistent with
ﬁndings recently published by Stolfo et al.27 The relation be-
tween clinical effects and MR reduction by medical therapy
is not well described in the literature. In contrast, it is well
known that improvement of signiﬁcant MR by CRT is
sustained and patients with less residual MR 6 months after
CRT have a better survival.28 In this study, it is clearly shown
that MR reduction is best related to NYHA class improve-
ment. The potential improvement in MR by HF therapy opti-
mization by a dedicated HF cardiologist may prevent in a
large number of HF patients the need for surgical or percuta-
neous mitral valve interventions.
Limitations
The major limitations of this study are the retrospective char-
acter and the limited number of patients. The latter was
mainly caused by our stringent study inclusion criteria, ex-
cluding patients in whom adjustment of therapy was started
before the ﬁrst echo in our centre. Also, approximately 20%
of patients were deemed to have irreversible HF and referred
for heart transplantation. Considering the total cohort of pa-
tients, a signiﬁcant MR reduction in over half of the patients
may therefore be an overestimation. On the other hand, ap-
proximately 10% of patients was referred back with medical
advices thought to be easily implemented by the referring
physician, and it may be expected that in these patients, even
a larger proportion of patients would have shown improve-
ment in MR. Finally, sacubitril/valsartan was not available at
the time of our study. Sacubitril/valsartan has been not only
shown to reduce the rate of HF hospitalization and cardiovas-
cular mortality in selected symptomatic patients with HF with
an LVEF <35%29 but also to reduce MR severity in patients
initially on optimal medical therapy with an ACE-I/ARB and
beta-blocker and signiﬁcant secondary MR.30
Conclusions
Initiation and up-titration of recommended HF therapy in pa-
tients referred to our tertiary HF outpatient clinic resulted in
signiﬁcant MR reduction in over half of the patients, empha-
sizing the importance of optimal medical treatment in these
very sick cardiac patients with otherwise grave prognosis.
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